Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VOYAGER: Dual Wavelength Fluorescence Imaging in IBD
NCT07258641Phase 2Not yet recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Jan 2026
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of adalimumab-680LT, risankizumab-800CW in inflammatory bowel disease (IBD), sponsored by University Medical Center Groningen. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
adalimumab-680LTrisankizumab-800CW
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT07258641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07258641.